Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Gross Profit (2016 - 2025)

Historic Gross Profit for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $2.7 billion.

  • Teva Pharmaceutical Industries' Gross Profit rose 2522.4% to $2.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.9 billion, marking a year-over-year increase of 1085.07%. This contributed to the annual value of $8.9 billion for FY2025, which is 1083.83% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Gross Profit stood at $2.7 billion for Q4 2025, which was up 2522.4% from $2.3 billion recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Gross Profit ranged from a high of $2.7 billion in Q4 2025 and a low of $1.6 billion during Q1 2023
  • In the last 5 years, Teva Pharmaceutical Industries' Gross Profit had a median value of $1.9 billion in 2021 and averaged $2.0 billion.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Gross Profit plummeted by 1365.85% in 2022 and then surged by 3644.07% in 2023.
  • Teva Pharmaceutical Industries' Gross Profit (Quarter) stood at $2.1 billion in 2021, then fell by 13.66% to $1.8 billion in 2022, then skyrocketed by 36.44% to $2.4 billion in 2023, then fell by 12.17% to $2.1 billion in 2024, then increased by 25.22% to $2.7 billion in 2025.
  • Its Gross Profit was $2.7 billion in Q4 2025, compared to $2.3 billion in Q3 2025 and $2.1 billion in Q2 2025.